N,N-DMT

N,N-DMT at a Glance

N,N-Dimethyltryptamine (DMT) is a naturally occurring tryptamine alkaloid and one of the classic serotonergic psychedelics, structurally a simple dimethylated relative of the neurotransmitter serotonin. It occurs across a remarkable range of plants — chacruna (Psychotria viridis), jurema (Mimosa), yopo (Anadenanthera) and many others — and is the visionary principle of ayahuasca ^{10,28Reference 10McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuascaView study →Reference 28Der Marderosian AH et al. · 1968Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyanaView study →}.

Two features make DMT unusual among psychedelics. First, it is orally inactive on its own: the gut and liver enzyme monoamine oxidase A (MAO-A) destroys it before it reaches the brain, so traditional ayahuasca pairs the DMT-bearing leaf with an MAO-inhibiting vine — Banisteriopsis caapi, rich in the β-carbolines harmine, harmaline and tetrahydroharmine ^{10,11Reference 10McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuascaView study →Reference 11Callaway JC et al. · 1999Pharmacokinetics of Hoasca alkaloids in healthy humansView study →}. Vaporised or injected, DMT bypasses this and produces an intense but very short experience. Second, DMT is endogenous — present at trace levels in mammalian tissue — which has made it a genuine, if unresolved, question in neuroscience ^{24,25Reference 24Barker SA · 2018N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and FunctionView study →Reference 25Barker SA · 2022Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMTView study →}.

Physiologically DMT has low toxicity, but it is a Schedule I / controlled substance in most countries, and its serious hazards are pharmacological (the MAOI combination, serotonergic drug interactions and transient cardiovascular effects) rather than organ toxicity ^{29,30Reference 29Gable RS · 2007Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloidsView study →Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →}. This page describes the research literature and offers no use or dosing guidance.

The Ayahuasca Solution: Oral Inactivation by MAO

The single most distinctive fact about DMT is that swallowing it does nothing — and the traditional Amazonian answer to that problem is the defining feature of ayahuasca pharmacology.

Orally, DMT is a substrate for monoamine oxidase A (MAO-A) in the gut wall and liver, which oxidatively deaminates it so rapidly that essentially none reaches the systemic circulation ^{11Reference 11Callaway JC et al. · 1999Pharmacokinetics of Hoasca alkaloids in healthy humansView study →}. Ayahuasca overcomes this by combining a DMT-bearing plant (chacruna or chaliponga) with the ayahuasca vine, whose β-carboline alkaloids are reversible MAO-A inhibitors. McKenna and colleagues’ classic analysis showed that the vine’s harmine, harmaline and tetrahydroharmine inhibit MAO strongly enough to let orally ingested DMT survive first-pass metabolism and become psychoactive ^{10Reference 10McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuascaView study →}. Human pharmacokinetic studies later confirmed the mechanism directly: after oral ayahuasca, DMT appears measurably in plasma alongside the harmala alkaloids, in a way it never does when DMT is given by mouth alone ^{11,32Reference 11Callaway JC et al. · 1999Pharmacokinetics of Hoasca alkaloids in healthy humansView study →Reference 32Callaway JC et al. · 1996Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuascaView study →}.

This same mechanism is also the compound’s headline safety liability: adding an MAO inhibitor to DMT is exactly the pharmacology that, with other serotonergic drugs, can precipitate serotonin toxicity (see Toxicity & Safety). The related β-carbolines harman and tetrahydroharman share the MAO-inhibiting motif to varying degrees.

Endogenous DMT

DMT is one of the few classic psychedelics that is also a natural constituent of the mammalian body. It was reported in human blood and urine decades ago, and the biosynthetic machinery exists: the enzyme indolethylamine-N-methyltransferase (INMT) methylates tryptamine (and its precursor N-methyltryptamine) to DMT, and INMT and DMT have been detected in mammalian brain and peripheral tissue ^{24,25,27Reference 24Barker SA · 2018N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and FunctionView study →Reference 25Barker SA · 2022Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMTView study →Reference 27Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyanaView study →}.

The debate is over quantity and meaning. Endogenous DMT is present only at trace (low-nanomolar) levels, and whether it is made in the brain in amounts sufficient to act as a signalling molecule — rather than a metabolic by-product — is unresolved. Dean and colleagues demonstrated that rat brain expresses the biosynthetic enzymes and that DMT concentrations there are comparable to those of established monoamine neurotransmitters, and that levels can rise under stress such as cardiac arrest ^{26Reference 26Dean JG et al. · 2019Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian BrainView study →}. Barker’s reviews lay out both the evidence and the many open questions honestly, cautioning against over-interpreting the “endogenous psychedelic” idea ^{24,25Reference 24Barker SA · 2018N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and FunctionView study →Reference 25Barker SA · 2022Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMTView study →}.

The most-discussed candidate function is DMT’s activity at the sigma-1 receptor: Fontanilla and colleagues identified DMT as an endogenous sigma-1 receptor agonist/regulator, a genuinely novel finding that reframes at least part of DMT’s biology outside the serotonin system ^{23Reference 23Fontanilla D et al. · 2009The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulatorView study →}. What role, if any, endogenous DMT plays in normal physiology, stress or altered states remains speculative.

What It's Used For

DMT’s pharmacology is well characterised at the receptor and human-phenomenology level, and a clinical-trials wave (DMT and ayahuasca for depression) is now under way. The honest framing: the acute psychedelic effect is firmly established in controlled human studies, the therapeutic signal is early and mostly rests on ayahuasca (a whole brew) plus a first generation of small isolated-DMT trials, and the neuroplasticity story is largely preclinical ^{1,14,22Reference 1Carbonaro TM · 2016Neuropharmacology of N,N-dimethyltryptamineView study →Reference 14Palhano-Fontes F et al. · 2019RCTRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialView study →Reference 22Ly C et al. · 2018Psychedelics Promote Structural and Functional Neural PlasticityView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Human therapeutic data are mostly the ayahuasca brew plus small early isolated-DMT trials, so isolate therapeutic scores stay modest by design.

01Acute psychedelic effect (5-HT2A)Promising68%Controlled human dose-response + EEG/fMRI; receptor pharmacology ^{1,4,5,7Reference 1Carbonaro TM · 2016Neuropharmacology of N,N-dimethyltryptamineView study →Reference 4Strassman RJ · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 5Strassman RJ et al. · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 7Timmermann C et al. · 2023Human brain effects of DMT assessed via EEG-fMRIView study →}

02Depression (antidepressant)Promising46%One ayahuasca RCT + open-label; first isolated-DMT trials ^{14,18,19Reference 14Palhano-Fontes F et al. · 2019RCTRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialView study →Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →Reference 19Erritzoe D et al. · 2026RCTA short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trialView study →}

03Neuroplasticity / psychoplastogenShaky38%Rodent + in-vitro dendritogenesis/behaviour ^{20,21,22Reference 20Cameron LP et al. · 2018AnimalEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and DepressionView study →Reference 21Cameron LP et al. · 2019AnimalChronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in RodentsView study →Reference 22Ly C et al. · 2018Psychedelics Promote Structural and Functional Neural PlasticityView study →}

04Anxiety / addiction / wellbeingShaky30%Observational ayahuasca cohorts + rodent models ^{17,20Reference 17Dos Santos RG et al. · 2016Systematic reviewAntidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trialsView study →Reference 20Cameron LP et al. · 2018AnimalEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and DepressionView study →}

05Endogenous / sigma-1 signallingShaky24%Mechanistic; biosynthesis + sigma-1 pharmacology, role unresolved ^{23,24,26Reference 23Fontanilla D et al. · 2009The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulatorView study →Reference 24Barker SA · 2018N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and FunctionView study →Reference 26Dean JG et al. · 2019Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian BrainView study →}

How DMT Works

DMT’s effects run through two main receptor systems — the serotonergic 5-HT2A axis that defines the psychedelic effect, and the sigma-1 receptor that ties into its endogenous biology — plus downstream plasticity signalling.

Serotonin 5-HT2A Receptor Agonism

The core mechanism. As a close structural analogue of serotonin, DMT is an agonist at 5-HT2A receptors, and 5-HT2A activation is necessary for the classic psychedelic effect — antagonists such as ketanserin blunt or abolish it, and 5-HT2A engagement drives the cortical desynchronisation seen on EEG ^{1,2,34Reference 1Carbonaro TM · 2016Neuropharmacology of N,N-dimethyltryptamineView study →Reference 2Nichols DE · 2016PsychedelicsView study →Reference 34Valle M et al. · 2016Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humansView study →}. DMT binds broadly across the serotonin-receptor family, including 5-HT2C and 5-HT1A, which shapes the overall profile ^{3,33Reference 3Ray TS · 2010Psychedelics and the human receptoromeView study →Reference 33Halberstadt AL · 2011Multiple receptors contribute to the behavioral effects of indoleamine hallucinogensView study →}.

Sigma-1 Receptor

DMT is an endogenous agonist/regulator of the sigma-1 receptor ^{23Reference 23Fontanilla D et al. · 2009The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulatorView study →} — a chaperone protein at the endoplasmic reticulum implicated in cellular stress responses, calcium signalling and neuroprotection. This is a non-serotonergic arm of DMT pharmacology and part of why its endogenous role is of interest, though its contribution to the acute subjective effect is thought to be minor relative to 5-HT2A.

Trace-Amine & Other Targets

DMT interacts with additional monoaminergic targets, including trace-amine-associated receptor 1 (TAAR1) and serotonin/other monoamine transporters, contributing to its complex pharmacology ^{1,3Reference 1Carbonaro TM · 2016Neuropharmacology of N,N-dimethyltryptamineView study →Reference 3Ray TS · 2010Psychedelics and the human receptoromeView study →}.

Neuroplasticity Signalling

Downstream of 5-HT2A, DMT engages TrkB–mTOR plasticity signalling, the proposed basis of its psychoplastogenic dendritic-growth effects in preclinical models ^{22Reference 22Ly C et al. · 2018Psychedelics Promote Structural and Functional Neural PlasticityView study →}.

The Subjective Experience & Its Neural Correlates

Uniquely among the classic psychedelics, DMT (vaporised or injected) produces an extremely rapid onset and short duration — an intense state peaking within a couple of minutes and largely resolving within 15–30 minutes. Controlled phenomenology studies describe immersive perceptual and “entity”-encounter reports at higher doses ^{9Reference 9Lawrence DW et al. · 2022Phenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experienceView study →}, and the state has been proposed as a pharmacological model of the near-death experience, with overlapping features on standardised questionnaires ^{8Reference 8Timmermann C et al. · 2018DMT Models the Near-Death ExperienceView study →}.

The neural signature is now partly mapped. Modern studies show DMT reduces alpha-band power and increases the diversity/complexity of spontaneous brain activity, with EEG-fMRI revealing widespread, hierarchy-flattening cortical changes whose time course tracks the subjective intensity ^{6,7Reference 6Timmermann C et al. · 2019Neural correlates of the DMT experience assessed with multivariate EEGView study →Reference 7Timmermann C et al. · 2023Human brain effects of DMT assessed via EEG-fMRIView study →}. Because the effect is so brief, target-controlled intravenous infusion is being explored to extend and stabilise the state for research and therapy ^{18Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →}.

Pharmacokinetics

DMT’s pharmacokinetics explain almost everything distinctive about it. By mouth it is essentially inactive — extensive first-pass deamination by MAO-A gives negligible oral bioavailability unless an MAO inhibitor is co-administered ^{11Reference 11Callaway JC et al. · 1999Pharmacokinetics of Hoasca alkaloids in healthy humansView study →}. Vaporised (smoked) or injected, it is absorbed and reaches the brain within seconds, producing an almost immediate effect ^{4Reference 4Strassman RJ · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →}. Elimination is very fast: DMT has a short plasma half-life (on the order of ~10–15 minutes after parenteral dosing), which is why the experience is so brief and why controlled research increasingly uses continuous infusion to sustain it ^{13,18Reference 13Good M et al. · 2023Pharmacokinetics of N,N-dimethyltryptamine in HumansView study →Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →}.

Metabolism is dominated by MAO-A, which converts DMT to indole-3-acetic acid as the major metabolite; minor routes include N-oxidation to DMT-N-oxide and other pathways, with metabolites recovered in urine after both oral (ayahuasca) and smoked dosing ^{12Reference 12Riba J et al. · 2015Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administrationView study →}. In the ayahuasca context, the co-ingested β-carbolines shift this picture: MAO-A inhibition raises and prolongs plasma DMT, and human plasma studies show DMT and the harmala alkaloids together after oral dosing ^{11,13,32Reference 11Callaway JC et al. · 1999Pharmacokinetics of Hoasca alkaloids in healthy humansView study →Reference 13Good M et al. · 2023Pharmacokinetics of N,N-dimethyltryptamine in HumansView study →Reference 32Callaway JC et al. · 1996Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuascaView study →}. Robust modern human PK of the isolated compound (Cmax, clearance, infusion modelling) is now being formally characterised ^{13Reference 13Good M et al. · 2023Pharmacokinetics of N,N-dimethyltryptamine in HumansView study →}.

Clinical Trials

Human research has moved from acute-effects and ayahuasca observational work into a first generation of controlled therapeutic trials, mostly in depression.

Last checked: July 2026.

Isolate vs. Plant Studies

The evidence base is unusually split by vehicle. The acute-effects and neuroimaging literature is overwhelmingly the isolated molecule — Strassman’s intravenous dose-response work and the modern EEG/fMRI and infusion studies all use pure DMT ^{4,5,7,18Reference 4Strassman RJ · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 5Strassman RJ et al. · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 7Timmermann C et al. · 2023Human brain effects of DMT assessed via EEG-fMRIView study →Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →}, a genuine strength for mechanism. The therapeutic literature, by contrast, leans heavily on the whole ayahuasca brew: the flagship treatment-resistant-depression RCT and the observational cohorts are ayahuasca, an inseparable combination of DMT with the MAO-inhibiting β-carbolines and other constituents ^{14,17Reference 14Palhano-Fontes F et al. · 2019RCTRapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialView study →Reference 17Dos Santos RG et al. · 2016Systematic reviewAntidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trialsView study →}. Attributing ayahuasca’s antidepressant effect to DMT alone is therefore premature — the harmala alkaloids alter DMT’s pharmacokinetics and have their own central activity. The isolated-DMT therapeutic trials now emerging (SPL026 and short-acting DMT interventions) are the studies that will actually test the molecule on its own ^{18,19Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →Reference 19Erritzoe D et al. · 2026RCTA short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trialView study →}. The preclinical plasticity work uses the isolate but in rodents/cells ^{20,22Reference 20Cameron LP et al. · 2018AnimalEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and DepressionView study →Reference 22Ly C et al. · 2018Psychedelics Promote Structural and Functional Neural PlasticityView study →}.

Prevalence in Nature

DMT is taxonomically widespread but unevenly distributed, reported from many plant families — prominently Rubiaceae (Psychotria), Fabaceae/Mimosoideae (Mimosa, Acacia, Anadenanthera), Malpighiaceae (Diplopterys) and Poaceae (grasses such as Phalaris) ^{10,28,30Reference 10McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuascaView study →Reference 28Der Marderosian AH et al. · 1968Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyanaView study →Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →}. Concentrations vary enormously with species, plant part, chemotype and provenance, and precise quantification is patchy.

Among the best-documented sources, the ayahuasca-admixture leaf chaliponga (Diplopterys cabrerana, formerly Banisteriopsis rusbyana) carries DMT as its major alkaloid at roughly 0.17–1.75% of dry leaf, generally higher than in chacruna (Psychotria viridis), the classic chacruna leaf of ayahuasca ^{27,28Reference 27Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyanaView study →Reference 28Der Marderosian AH et al. · 1968Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyanaView study →}. Jurema (Mimosa) concentrates DMT in its root bark, and yopo (Anadenanthera peregrina) seeds carry it alongside the related tryptamines bufotenin and 5-MeO-DMT. DMT also occurs at trace levels in mammals, including human tissue, where it is biosynthesised by INMT ^{24,26Reference 24Barker SA · 2018N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and FunctionView study →Reference 26Dean JG et al. · 2019Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian BrainView study →}. Where a plant is famous as a “DMT source”, the reputation usually reflects reliable, extractable content in a specific tissue rather than uniform occurrence.

Two names in circulation do not survive checking. Osteophloeum platyspermum, a Myristicaceae tree named in earlier ethnobotanical reports as a tryptamine-bearing hallucinogen, was included in the quantitative survey of orally active Myristicaceous plants — which found its only indolic base to be N-methyl-tryptophan methyl ester, not DMT. Across that study’s 27 Myristicaceous bark and leaf samples, alkaloid loads ran 0.04–0.25 mg/g dry weight and no β-carbolines were detected at all ^{36Reference 36McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: constituents of orally-active Myristicaceous hallucinogensView study →}. And common reed (Phragmites australis) appears as a DMT source across many secondary compilations without a validated quantitative figure behind it for the species — the reports are qualitative and not consistently replicated in the pharmacological literature.

Major Natural Sources

Source	Plant part	Reported DMT content
Chaliponga (Diplopterys cabrerana)	dried leaf	~0.17–1.75% dry wt 27Reference 27Agurell S et al. · 1968Alkaloid content of Banisteriopsis rusbyanaView study →
Chacruna (Psychotria viridis)	dried leaf	typically lower than chaliponga; variable 28Reference 28Der Marderosian AH et al. · 1968Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyanaView study →
Jurema (Mimosa spp.)	root bark	concentrated in root bark (variable)
Yopo (Anadenanthera peregrina)	seed	present with bufotenin / 5-MeO-DMT

Figures are for the specified tissue and are comparative; only the chaliponga range rests on a directly cited quantitative study here — the other rows are qualitative pending measured figures (a gap tracked separately).

Discovery & Synthesis

DMT was first synthesised in the laboratory in 1931 by the Canadian chemist Richard Manske, before its natural occurrence was known. Its identification as a natural plant alkaloid came in the mid-1950s, when Fish, Johnson and Horning characterised it from Anadenanthera (cohoba) snuff and related sources — establishing that the compound long used in Amazonian and Caribbean snuffs and brews was DMT. Its role as the active principle of ayahuasca was clarified over the following decades, culminating in McKenna and colleagues’ demonstration that the brew’s activity depends on β-carboline MAO inhibition protecting the leaf’s DMT ^{10Reference 10McKenna DJ et al. · 1984Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuascaView study →}.

Because DMT is a structurally simple tryptamine, it is readily prepared by synthesis and is also extracted from plant material; the chemistry is well known and unremarkable. Its manufacture, possession and supply are, however, legally controlled in most jurisdictions (see Toxicity & Safety), so legitimate production is confined to licensed research and pharmaceutical settings — the isolated-DMT clinical programmes use pharmaceutical-grade material such as DMT fumarate ^{18Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →}.

Patents: not yet researched.

Toxicity & Safety

DMT’s physiological toxicity is low — it does not have the organ-toxicity profile of, say, a hepatotoxin — but that is not where its risks lie. The real safety story is pharmacological and legal: dangerous drug combinations, transient cardiovascular effects, acute psychological risk, and controlled-substance status ^{29,30Reference 29Gable RS · 2007Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloidsView study →Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →}.

Safety at a Glance

🍄 PsychedelicSerotonin riskControlled substance

• Low direct physiological toxicity. DMT itself has a wide margin against organ toxicity, is not associated with dependence, and is rapidly metabolised ^{29Reference 29Gable RS · 2007Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloidsView study →}.
• MAOI / serotonergic-drug combination is the key hazard. The MAO-inhibitor pairing that makes oral DMT active (ayahuasca) is exactly the pharmacology that, with SSRIs/SNRIs, MAOIs or other serotonergic agents, can precipitate serotonin toxicity; fatalities have occurred with tryptamine-plus-MAOI preparations ^{30,31Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →Reference 31Sklerov J et al. · 2005A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparationView study →}.
• Transient cardiovascular effects. DMT sharply and briefly raises blood pressure and heart rate, a concern for people with cardiovascular disease ^{5Reference 5Strassman RJ et al. · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →}.
• Acute psychological intensity. Overwhelming fear, disorientation and destabilisation can occur, especially uncontrolled or in vulnerable individuals; screening and setting matter in research ^{4,9Reference 4Strassman RJ · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 9Lawrence DW et al. · 2022Phenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experienceView study →}.
• Controlled / Schedule I substance. DMT (and ayahuasca) are illegal to possess or supply in most countries, with narrow religious/research exemptions ^{30Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →}.

Full Safety & Interactions Detail

Serotonin toxicity (the load-bearing risk). Oral DMT activity requires MAO-A inhibition, and MAO inhibitors combined with other serotonergic drugs are a classic cause of serotonin syndrome/toxicity — so co-use of ayahuasca (or DMT + a harmala/MAOI) with SSRIs, SNRIs, MAOIs, tramadol, triptans or other serotonergic agents is the principal serious hazard ^{30Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →}. A documented fatality involved a tryptamine-plus-β-carboline “ayahuasca-like” preparation ^{31Reference 31Sklerov J et al. · 2005A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparationView study →}. Because MAO inhibition also blocks tyramine breakdown, the standard MAOI dietary/drug cautions apply to ayahuasca-style use.

Cardiovascular. DMT produces a transient but marked rise in blood pressure and heart rate and increases circulating stress hormones (e.g. cortisol, prolactin, growth hormone) ^{5Reference 5Strassman RJ et al. · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →}; the acute pressor effect is a real consideration for people with hypertension or cardiovascular disease.

Psychological. The acute experience can be overwhelming, with intense fear or disorientation; there is a general risk of destabilising individuals with, or predisposed to, psychotic illness. Research protocols screen participants and control set and setting for this reason ^{4,9Reference 4Strassman RJ · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 9Lawrence DW et al. · 2022Phenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experienceView study →}.

Reproductive note (prose only). No adequate reproductive-toxicity dataset exists for isolated DMT, and no isolate-level pregnancy/lactation verdict is issued on this molecule page; such decisions belong to the herb/product context where intake is decided.

Legal. DMT is listed under the UN Convention on Psychotropic Substances and is a Schedule I substance in the United States and a controlled substance in most countries; ayahuasca is likewise controlled, with limited religious-use exemptions in some jurisdictions ^{30Reference 30Grob CS et al. · 1996Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in BrazilView study →}. This is itself a material “safety” issue: possession and supply carry legal risk.

Dosage

There is no established or recommended dose for DMT — it is a controlled substance, and the figures below simply describe amounts used in the research literature, not a recommendation. In controlled studies, intravenous DMT has been given at roughly 0.1–0.4 mg/kg (fumarate), spanning a threshold to a fully psychedelic dose ^{4,5Reference 4Strassman RJ · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →Reference 5Strassman RJ et al. · 1994Dose-response study of N,N-dimethyltryptamine in humansView study →}; vaporised doses studied are broadly comparable (on the order of tens of milligrams). Orally, DMT is inactive unless combined with an MAO inhibitor — the ayahuasca route — where dose is governed by the brew’s combined DMT-plus-β-carboline content rather than a single figure ^{11,32Reference 11Callaway JC et al. · 1999Pharmacokinetics of Hoasca alkaloids in healthy humansView study →Reference 32Callaway JC et al. · 1996Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuascaView study →}. Continuous intravenous infusion paradigms are being used in research to extend the otherwise very brief effect ^{18Reference 18James E et al. · 2023Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participantsView study →}.

These are amounts studied in research and are not a personal recommendation.

References

1. Carbonaro TM, Gatch MB (2016). Neuropharmacology of N,N-dimethyltryptamine. Brain Research Bulletin. https://pubmed.ncbi.nlm.nih.gov/27126737/
2. Nichols DE (2016). Psychedelics. Pharmacological Reviews. https://pubmed.ncbi.nlm.nih.gov/26841800/
3. Ray TS (2010). Psychedelics and the human receptorome. PLoS One. https://pubmed.ncbi.nlm.nih.gov/20126400/
4. Strassman RJ, Qualls CR (1994). Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Archives of General Psychiatry. https://pubmed.ncbi.nlm.nih.gov/8297216/
5. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994). Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry. https://pubmed.ncbi.nlm.nih.gov/8297217/
6. Timmermann C, et al. (2019). Neural correlates of the DMT experience assessed with multivariate EEG. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/31745107/
7. Timmermann C, et al. (2023). Human brain effects of DMT assessed via EEG-fMRI. Proceedings of the National Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/36940333/
8. Timmermann C, et al. (2018). DMT Models the Near-Death Experience. Frontiers in Psychology. https://pubmed.ncbi.nlm.nih.gov/30174629/
9. Lawrence DW, et al. (2022). Phenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experience. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/35610230/
10. McKenna DJ, Towers GH, Abbott F (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/6587171/
11. Callaway JC, et al. (1999). Pharmacokinetics of Hoasca alkaloids in healthy humans. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/10404423/
12. Riba J, et al. (2015). Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration. Drug Testing and Analysis. https://pubmed.ncbi.nlm.nih.gov/25069786/
13. Good M, et al. (2023). Pharmacokinetics of N,N-dimethyltryptamine in Humans. European Journal of Drug Metabolism and Pharmacokinetics. https://pubmed.ncbi.nlm.nih.gov/37086340/
14. Palhano-Fontes F, et al. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Medicine. https://pubmed.ncbi.nlm.nih.gov/29903051/
15. Galvão-Coelho NL, et al. (2020). Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. Journal of Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/32648790/
16. Zeifman RJ, et al. (2019). The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/31798447/
17. Dos Santos RG, et al. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials. Therapeutic Advances in Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/27354908/
18. James E, et al. (2023). Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants. Frontiers in Psychiatry. https://pubmed.ncbi.nlm.nih.gov/38274414/
19. Erritzoe D, et al. (2026). A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/41699126/
20. Cameron LP, et al. (2018). Effects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. ACS Chemical Neuroscience. https://pubmed.ncbi.nlm.nih.gov/29664276/
21. Cameron LP, et al. (2019). Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chemical Neuroscience. https://pubmed.ncbi.nlm.nih.gov/30829033/
22. Ly C, et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/29898390/
23. Fontanilla D, et al. (2009). The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. https://pubmed.ncbi.nlm.nih.gov/19213917/
24. Barker SA (2018). N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. Frontiers in Neuroscience. https://pubmed.ncbi.nlm.nih.gov/30127713/
25. Barker SA (2022). Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/35064294/
26. Dean JG, et al. (2019). Biosynthesis and Extracellular Concentrations of N,N-dimethyltryptamine (DMT) in Mammalian Brain. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/31249368/
27. Agurell S, Holmstedt B, Lindgren JE (1968). Alkaloid content of Banisteriopsis rusbyana. American Journal of Pharmacy and the Sciences Supporting Public Health. https://pubmed.ncbi.nlm.nih.gov/5698439/
28. Der Marderosian AH, Pinkley HV, Dobbins MF (1968). Native use and occurrence of N,N-dimethyltryptamine in the leaves of Banisteriopsis rusbyana. American Journal of Pharmacy and the Sciences Supporting Public Health. https://pubmed.ncbi.nlm.nih.gov/5698438/
29. Gable RS (2007). Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction. https://pubmed.ncbi.nlm.nih.gov/17207120/
30. Grob CS, et al. (1996). Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. The Journal of Nervous and Mental Disease. https://pubmed.ncbi.nlm.nih.gov/8596116/
31. Sklerov J, et al. (2005). A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. Journal of Analytical Toxicology. https://pubmed.ncbi.nlm.nih.gov/16356341/
32. Callaway JC, et al. (1996). Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. Journal of Analytical Toxicology. https://pubmed.ncbi.nlm.nih.gov/8889686/
33. Halberstadt AL, Geyer MA (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/21256140/
34. Valle M, et al. (2016). Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. European Neuropsychopharmacology. https://pubmed.ncbi.nlm.nih.gov/27039035/
35. Morales-García JA, et al. (2020). N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Translational Psychiatry. https://pubmed.ncbi.nlm.nih.gov/32989216/
36. McKenna DJ, Towers GH, Abbott FS (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: constituents of orally-active Myristicaceous hallucinogens. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/6521493/

View all 36 references▾